Related Experiment Video

Updated: Oct 15, 2026

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
04:27

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Published on: May 4, 2020

Indomethacin therapy in premature infants with patent ductus arteriosus and oliguria

T F Yeh, A Wilks, J Luken

    Developmental Pharmacology and Therapeutics
    |January 1, 1986
    PubMed

    Insights

    This study found that giving indomethacin and furosemide together safely treated premature infants with patent ductus arteriosus (PDA) and kidney problems. The treatment improved kidney function and reduced infant distress.

    Area of Science:

    • Neonatal Medicine
    • Pediatric Cardiology
    • Nephrology

    Background:

    • Premature infants often develop patent ductus arteriosus (PDA).
    • Oliguria due to prerenal failure is a common complication in these infants.
    • Current treatments for PDA and oliguria may have limitations.

    Purpose of the Study:

    • To evaluate the safety and efficacy of simultaneous indomethacin and furosemide administration.
    • To assess the impact on patent ductus arteriosus (PDA) closure.
    • To determine the effect on renal function in premature infants with oliguria.

    Main Methods:

    • Eight premature infants with PDA and oliguria received a single intravenous dose of indomethacin (0.3 mg/kg) and furosemide (1 mg/kg).
    • Infant response was monitored via echocardiogram and clinical assessment.
    • Renal function was assessed by measuring urine output (U/O), glomerular filtration rate (GFR), and fractional excretion of sodium (FENa) and chloride (FECl).

    Main Results:

    • Four out of eight infants experienced closure of the PDA.
    • Two infants showed improvement in echocardiogram findings and reduced clinical distress.
    • Significant increases in U/O, GFR, FENa, and FECl were observed post-administration.

    Conclusions:

    • Simultaneous administration of indomethacin and furosemide appears to be a safe and effective treatment option.
    • This combined therapy can lead to PDA closure and improved renal function in premature infants.
    • The findings support the use of this combined approach for infants with PDA and oliguria.

    More Related Videos

    Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis04:36

    Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis

    Published on: October 2, 2020

    In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus11:59

    In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus

    Published on: April 28, 2023

    Related Concept Videos

    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

    Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
    ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

    Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
    These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
    Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

    Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

    Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
    Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
    Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

    Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

    The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
    Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
    Drug Dosing: Infants and Children01:29

    Drug Dosing: Infants and Children

    Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...